• Aucun résultat trouvé

PERSONALISED MEDICINE

N/A
N/A
Protected

Academic year: 2022

Partager "PERSONALISED MEDICINE"

Copied!
1
0
0

Texte intégral

(1)

Budget: €3.3bn

€1.6bn from Horizon 2020

Strengthen Europe’s healthcare industry

INNOVATIVE MEDICINES INITIATIVE

about 20 % of Horizon 2020’s budget to encourage highly innovative SMEs

BETTER ACCESS TO LOANS public-private partnership

to develop better and safer medicines

between €7.5m - €75m through the InnovFin Infectious Diseases initiative SME SUPPORT

SUPPORT EUROPEAN COORDINATION IN HEALTH AND DISEASE RESEARCH create synergies

Develop EU countries’ health research and innovation strategies

PERSONALISED MEDICINE

FOCUSING ON CITIZENS' HEALTH

PERSONALISED MEDICINE

tailor-made prevention, diagnosis and treatment for individuals or groups of individuals

Enabling

HEALTHIER, MORE PRODUCTIVE LIVES

€ € €

Significant EU investments in research on personalised medicine to

DRIVE HEALTHCARE INNOVATION Establish Europe as a global leader in healthcare industry and innovation, and create jobs and economic growth TREAT PATIENTS WITH THE THERAPIES

THAT WORK BEST FOR THEM many common medicines are not effective for many patients

AVOID ADVERSE REACTIONS TO MEDICINES

6% of acute hospital admissions are due to serious adverse reactions to medicines

CUT HEALTHCARE COSTS as Europe’s population ages and chronic diseases become more prevalent

Research and innovation investment in better health

Personalised medicine integrates information from multiple sources to make

HEALTHCARE SMARTER, BETTER AND MORE COSTEFFICIENT.

7

th

Framework Programme

2007–2013

Horizon 2020

First 3 years 2014-2017

167 projects on personalised medicine

€1334 million in EU funding.

209 projects on personalised

medicine

€872 million in EU funding

What is our strategy?

PROMOTE PERSONALISED HEALTH AND CARE RESEARCH

EU funding stimulates collaborations between researchers, health research funders, regions, countries, policymakers and other stakeholders

empower patients and involve healthcare providers develop a medical model using individuals’

genotypes and phenotypes

for example molecular profiling, medical imaging, and lifestyle data

MORE INFORMATION:

https://ec.europa.eu/research/health/personalised www.icpermed.eu

@EUScienceInnov

© European Union, 2017

Make the EU a stronger global player

COOPERATION SCHEMES with Canada, China, Australia, US and others to implement objectives such as common guidelines and best practices

INTERNATIONAL ENGAGEMENTS science diplomacy and

global scientific collaboration

Research and Innovation

Références

Documents relatifs

Having information on firms’ mode of exit, by failure or by acquisition, we run a discrete time competing risk model to investigate the relationship between the quality of

The second is regarding the sustainability of work (and aims at identifying innovation processes focusing on sustaining work, perceived from the angle of social insertion or

IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe and operates as

Therefore, we have created an inventory of components for processing Dutch natural language, enabling to encode Dutch text as structured SNOMED CT output.. This

Finally, since the aim of the present paper is to develop a method to assess the vulnerability (and the risk) related to tephra fallout, thematic vulnerability maps might be

• Determine the main role of HPs within patient associations • Create bridges between associations and healthcare institutions • Recognize that patient association members can

TRECENTO GLOBAL HEALTHCARE s’est conformé aux règles comptables prescrites par le règlement du comité de la réglementation comptable n°2003-02 du 2 octobre

For example: manager responsible for managing technological change, monitoring and observation of competition, leading the monitoring unit, managing economic and